IL17A and type 2 diabetes mellitus: Notably, the findings define the role of IL-17A in Type II diabetes-induced non-proliferative diabetic retinopathy, while further defining the efficacy of anti-IL-17A as a potentially novel therapeutic for non-proliferative diabetic retinopathy.